Floatz logo

Silatecan

GBM

Arno TherapeuticsSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

10 Active assets in the GBM cohort.

Asset / SponsorPhaseRating
Lapatinib
National Cancer Institute (NCI)
Phase 2BB
LENVATINIB
Tel Aviv Medical Center
Phase 2BB
CHLOROTOXIN
TransMolecular
Phase 2BB
FET
Thomas Hope
Phase 2B
MANNITOL
Northwell Health
Phase 2B

View all 18 →

Same molecule, other indications

Silatecan is also rated in:

glioblastomaDormant
CCC
Indicative ·
53 / 100
View asset →
gliosarcomaDormant
CCC
Indicative ·
53 / 100
View asset →
neoplasmDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →